LENSAR Inc.
(LNSR)
undefined
undefined%
At close: undefined
7.55
0.73%
After-hours Dec 13, 2024, 04:00 PM EST
Company Description
LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism.
Its LENSAR Laser System incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision.
The company was incorporated in 2004 and is headquartered in Orlando, Florida.
LENSAR Inc.
| Country | United States |
| IPO Date | Oct 2, 2020 |
| Industry | Medical - Devices |
| Sector | Healthcare |
| Employees | 130 |
| CEO | Nicholas T. Curtis |
Contact Details
Address: 2800 Discovery Drive Orlando, Florida United States | |
| Website | https://www.lensar.com |
Stock Details
| Ticker Symbol | LNSR |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001320350 |
| CUSIP Number | 52634L108 |
| ISIN Number | US52634L1089 |
| Employer ID | 32-0125724 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Nicholas T. Curtis | President, Chief Executive Officer & Director |
| Alan B. Connaughton | Chief Operating Officer |
| Thomas R. Staab II, CPA | Chief Financial Officer & Secretary |
| Kendra W. Wong | Principal Accounting Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 07, 2024 | 10-Q | Quarterly Report |
| Nov 07, 2024 | 8-K | Current Report |
| Sep 06, 2024 | 4 | Filing |
| Aug 29, 2024 | 4 | Filing |
| Aug 23, 2024 | 4 | Filing |
| Aug 20, 2024 | 4 | Filing |
| Aug 14, 2024 | 4 | Filing |
| Aug 12, 2024 | 4 | Filing |
| Aug 08, 2024 | 10-Q | Quarterly Report |